As an experienced biotech investor, you are familiar with the typical following phases:
0. Company and technology only known by a few. The best time to "get in a given stock," as they can often be purchased for pennies.
1. This is always followed by a "euphoric period" when valuations are completely momentum-based, as "the story" gets disseminated to the public and retail investors learn about the company.
2. This is then typically followed-up by a period of disillusionment, when true market size and the realities of bringing a product to market are more fully understood. However, outside of phase 0, this is usually the best opportunity to "get in on the cheap," for most. Institutional ownership also rises near the end of this phase.
3. Finally, if the company is successful in bringing its product to market, valuations are based on real metrics (earnings) and long shareholders are rewarded appropriately with real long-term gains.
We are at the tail-end of phase #1 above.
AH prices mean virtually nothing unless there is volume behind them.
Only 2509 shares traded so far in AH. Not enough.
Tomorrow morning at 9:30 will be telling, though.
We're not off to a good start, post-conference.
Sell the news? Wait, there wasn't any news!
I tend to agree.
About the only thing that would send this stock to $15 in 10 days is the bioprinting of Jesus before Christmas!
Bad earnings from various DOW components, general attack on 3D marketplace, pessimism about the budget deal in Congress, no news from ONVO conference.
In other words, a perfect storm for shorts (at least for a day).
I'm optimistic, but the liver assay product will not be available until next December, according to the CEO.
Congrats on your persistence.
Has Congress voted on that bill yet?
They go on recess after Friday through the end of the year, so they need to vote on it this week, or during the first week in January.